GT-02287
Overview
Mermaid diagram (expand to render)
GT-02287 is a small molecule drug candidate developed by [Gain Therapeutics](/companies/gain-therapeutics) using its proprietary computer-based drug discovery platform to identify allosteric modulators of the glucocerebrosidase (GCase) enzyme for the treatment of Parkinson's disease and potentially other neurodegenerative disorders associated with GCase dysfunction["@gain2024"]. The drug represents a novel approach to targeting the GBA1 gene variant, which is one of the most significant genetic risk factors for Parkinson's disease.
The GBA1 gene encodes glucocerebrosidase, a lysosomal enzyme that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. Mutations in GBA1 represent the most common genetic risk factor for Parkinson's disease, with carriers showing earlier onset, more rapid progression, and increased risk of cognitive decline["@sidransky2009"]. GT-02287 aims to address this by enhancing residual GCase activity through allosteric stabilization, potentially slowing disease progression in GBA1-associated Parkinson's disease.
Background: GBA1 and Parkinson's Disease
Genetic Epidemiology
The GBA1 gene encodes glucocerebrosidase, a crucial lysosomal enzyme that hydrolyzes glucocerebroside into glucose and ceramide as part of the sphingolipid catabolic pathway. While complete loss of GCase activity causes Gaucher disease, a recessive lysosomal storage disorder, heterozygous carriers of GBA1 mutations face a significantly elevated risk of developing Parkinson's disease[@sidransky2009].
Population studies have consistently demonstrated the strong association between GBA1 mutations and Parkinson's disease risk:
- Ashkenazi Jewish Population: Approximately 15-20% of PD patients carry GBA1 mutations, compared to 3-4% of the general population[@odonnell2022]
- European Ancestry: 5-10% of PD patients carry pathogenic GBA1 variants[@liu2024]
- Asian Populations: Lower but still significant prevalence (2-5%) of GBA1-associated PD[@sun2021]
The identification of GBA1 as a major Parkinson's disease risk gene has transformed our understanding of the disease pathogenesis and opened new therapeutic avenues targeting lysosomal dysfunction.
Pathophysiological Mechanisms
The link between GBA1 mutations and Parkinson's disease involves multiple interconnected mechanisms:
1. Reduced GCase Activity
GBA1 mutations, even in heterozygous carriers, result in reduced GCase enzyme activity (typically 30-70% of wild-type levels). This partial deficiency impairs lysosomal function and leads to accumulation of glucocerebroside substrates[@gokeralpan2023]. The resulting lipid dysregulation affects cellular membranes, protein trafficking, and organelle function within dopaminergic neurons.
2. Alpha-Synuclein Aggregation
A critical finding connecting GBA1 to Parkinson's disease pathogenesis is the direct interaction between GCase and alpha-synuclein. Studies have demonstrated that:
- GCase deficiency promotes alpha-synuclein aggregation through multiple mechanisms[@mazzulli2011]
- Alpha-synuclein can inhibit GCase activity, creating a vicious cycle[@xu2021]
- Glucocerebroside accumulation stabilizes toxic alpha-synuclein oligomers[@taguchi2024]
- The GCase-alpha-synuclein relationship represents a pathogenic feed-forward loop
3. Lysosomal Dysfunction
GBA1 mutations impair lysosomal homeostasis beyond GCase itself:
- Reduced autophagic flux compromises clearance of damaged organelles and protein aggregates[@miranda2022]
- Impaired mitophagy leads to accumulation of dysfunctional mitochondria
- Altered lipid metabolism affects lysosomal membrane composition and trafficking
4. Neuroinflammation
GBA1 deficiency promotes neuroinflammation through:
- Activation of microglia and astrocytes in response to accumulated substrates[@booth2023]
- Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Enhanced NLRP3 inflammasome activation
5. Endoplasmic Reticulum Stress
Mutant GCase proteins undergo misfolding, triggering ER stress responses:
- Activation of unfolded protein response (UPR) pathways[@kolodny2022]
- Impaired calcium homeostasis
- Pro-apoptotic signaling cascades
Clinical Phenotype of GBA1-Associated Parkinson's Disease
GBA1-PD patients exhibit distinct clinical characteristics compared to idiopathic Parkinson's disease:
| Feature | GBA1-PD | Idiopathic PD |
|---------|---------|---------------|
| Age at onset | 55-60 years | 60-65 years |
| Cognitive impairment | More common, earlier | Less common |
| Motor symptoms | Similar presentation | Standard presentation |
| Non-motor symptoms | Higher prevalence | Lower prevalence |
| Disease progression | More rapid | Slower progression |
| Treatment response | Variable | Generally good |
Cognitive Impairment
GBA1-PD patients face substantially increased risk of developing Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). Studies indicate that 30-50% of GBA1-PD patients develop dementia within 10 years of diagnosis, compared to 15-25% of idiopathic PD patients[@winderrhodes2023].
Non-Motor Symptoms
GBA1-PD patients often exhibit:
- More severe olfactory dysfunction
- Higher prevalence of REM sleep behavior disorder
- More frequent autonomic dysfunction
- Greater burden of neuropsychiatric symptoms (depression, anxiety)[@pchelina2024]
Diagnosis and Screening
Genetic testing for GBA1 mutations is increasingly recommended in:
- Patients with early-onset PD (<60 years)
- Patients with family history of PD or Gaucher disease
- Patients with rapid cognitive decline
- Ashkenazi Jewish ancestry
Testing typically involves:
Panel testing for common GBA1 mutations
Full gene sequencing for comprehensive analysis
Confirmation of pathogenic variants with segregation studiesCommon pathogenic variants include:
- N370S (most common in Ashkenazi Jewish population)
- L444P (severe, associated with neuronopathic Gaucher)
- R496H
- D409H
- 84insG
Mechanism of Action
Allosteric Modulation of GCase
GT-02287 represents a novel approach to enzyme enhancement through allosteric modulation rather than traditional active-site targeting. The drug binds to a previously unidentified allosteric site on the glucocerebrosidase enzyme, distinct from the catalytic site and the substrate-binding pocket[@gain2024].
The allosteric mechanism offers several advantages over traditional enzyme replacement or gene therapy approaches:
Enzyme Stabilization: GT-02287 binding stabilizes GCase in its active conformation, increasing the proportion of properly folded, functional enzyme within lysosomes[@schapira2020].
Substrate-Independent Activity: Unlike competitive inhibitors that affect substrate binding, GT-02287 enhances enzyme activity without interfering with the natural substrate (glucocerebroside), allowing normal cellular metabolism to continue[@mazzulli2011].
Residual Activity Preservation: The drug may enhance activity of partially functional mutant GCase variants that retain some catalytic capability but are thermodynamically unstable[@siegal2023].Structural Basis
Computational modeling and structural studies have identified the allosteric binding site in a region distinct from the catalytic domain. This site is conserved across species, suggesting evolutionary importance and potential for drug development[@wang2021]. The binding site involves key residues that stabilize the enzyme's active conformation, reducing misfolding and enhancing lysosomal trafficking.
Advantages Over Alternative Approaches
| Approach | Example | Mechanism | Delivery | BBB Penetration |
|----------|---------|-----------|----------|-----------------|
| Enzyme stabilizer | GT-02287 | Allosteric modulation | Oral | Good |
| Gene therapy | PR001, AAV-GCASE | Gene replacement | AAV vector | Limited |
| Substrate reduction | Eliglustat, Lucerastat | GCase substrate inhibition | Oral | Good |
| Chaperone | Ambroxol | Pharmacological chaperone | Oral | Limited |
The oral bioavailability and blood-brain barrier penetration represent significant advantages over enzyme replacement therapies that cannot cross the BBB and gene therapy approaches that show limited CNS distribution[@sardi2024].
Clinical Development
Preclinical Studies
In Vitro Studies
Preclinical characterization of GT-02287 demonstrated dose-dependent increases in GCase activity in multiple cellular models:
- Wild-type GCase: 40-60% activity enhancement at 10μM concentration
- GBA1 mutant cell lines: Variable enhancement depending on specific mutation (N370S showing ~30% increase, L444P showing ~15% increase)
- Patient-derived neurons: Increased GCase activity in neurons from GBA1-PD carriers[@zunke2022]
In Vivo Studies
Pharmacokinetic studies in rodents demonstrated:
- Brain exposure: Significant brain concentrations achieved (brain-to-plasma ratio ~0.3)
- Half-life: Suitable for once-daily dosing (6-8 hour half-life)
- Distribution: Good tissue distribution including brain, liver, and spleen[@gain2023]
Disease Model Studies
In mouse models of GBA1-associated Parkinson's disease:
- Reduced alpha-synuclein accumulation in substantia nigra
- Improved motor performance on behavioral tests
- Decreased markers of neuroinflammation
- Improved lysosomal function markers[@burbulla2023]
Toxicology
Preclinical toxicology in rodents and non-human primates showed:
- No significant adverse effects at doses up to 100mg/kg
- No CNS toxicity observed
- Minimal off-target binding
- Acceptable safety margin for clinical development[@gain2023a]
Clinical Trials
Phase 1 Study (NCT06218389)
A first-in-human Phase 1 study initiated in 2024 to evaluate:
- Primary endpoints: Safety and tolerability in healthy volunteers
- Secondary endpoints: Pharmacokinetic parameters, food effect
- Dose escalation: Single ascending dose followed by multiple ascending dose
Status: Currently recruiting (as of early 2025)
Expected Phase 2 Studies
Planning underway for Phase 2 studies in GBA1-associated Parkinson's disease patients:
- Population: Patients with confirmed GBA1 mutations and Parkinson's disease diagnosis
- Endpoints: Change in GCase activity, motor scores (MDS-UPDRS), biomarkers
- Duration: 52-week treatment period
Therapeutic Potential
Parkinson's Disease
GBA1 mutations affect approximately 5-10% of Parkinson's disease patients, representing a substantial patient population that may benefit from disease-modifying therapies targeting GCase dysfunction[@balestrino2020]. GT-02287's mechanism addresses the underlying pathophysiology rather than just symptoms, potentially offering disease modification.
Potential benefits include:
Motor Symptom Improvement: Enhanced GCase activity may reduce alpha-synuclein aggregation, potentially slowing dopaminergic neuron loss
Cognitive Protection: GBA1-PD patients have higher risk of dementia; GCase enhancement may protect against cognitive decline
Disease Modification: By addressing upstream pathology, GT-02287 may slow disease progression rather than just alleviating symptomsBroader Applications
Beyond Parkinson's disease, GCase dysfunction has been implicated in other disorders:
- Gaucher Disease: Although primarily treated with enzyme replacement, GT-02287 may offer oral alternative for neuronopathic forms
- Dementia with Lewy Bodies: GBA1 mutations increase risk; GCase enhancement may be beneficial
- Multiple System Atrophy: Some evidence of GCase involvement in this atypical parkinsonian disorder[@parnetti2024]
Competitive Landscape
GBA-Targeting Therapeutics
The GBA1-PD therapeutic landscape includes multiple approaches:
| Drug/Approach | Company | Stage | Mechanism |
|---------------|---------|-------|-----------|
| GT-02287 | Gain Therapeutics | Phase 1 | Allosteric modulator |
| PR001 | Prevail Therapeutics | Phase 1/2 | Gene therapy (AAV) |
| Ambroxol | Various | Research | Pharmacological chaperone |
| Eliglustat | Sanofi | Approved (Gaucher) | Substrate reduction |
| Venglustat | Sanofi | Phase 2 | Substrate reduction |
Competitive Analysis
Advantages of GT-02287
Oral Bioavailability: Unlike gene therapy approaches requiring intracranial injection, GT-02287 can be administered orally, improving patient compliance and allowing for dose adjustment[@wood2024].
BBB Penetration: The molecule achieves meaningful brain concentrations, targeting the central nervous system where neurodegeneration occurs in Parkinson's disease.
Allosteric Mechanism: Provides a novel mechanism distinct from substrate reduction or enzyme replacement approaches, potentially offering additive or synergistic benefits when combined with other therapies.
Non-Immunogenic: Small molecule approach avoids immune reactions associated with protein or gene-based therapies.Challenges and Limitations
Modest Activity Enhancement: Maximum activity increase of 40-60% in wild-type, lower for severe mutations — may be insufficient for patients with complete GCase loss.
Mutation-Dependent Response: Different GBA1 mutations respond differently; some severely compromised enzymes may not respond to allosteric stabilization.
Chronic Dosing Required: Unlike gene therapy providing long-term expression, small molecules require daily dosing for sustained effect.
Combination Uncertainty: Optimal combination strategies with standard PD medications remain undefined.Market Considerations
The GBA1-PD market represents an underserved population with significant unmet need. Current treatments address symptoms but not underlying pathology. GT-02287's oral delivery and brain penetration position it competitively against invasive gene therapy approaches[@mcgurran2024].
Market Size Estimates
- GBA1-PD Patient Population: Approximately 500,000-1,000,000 patients worldwide (5-10% of total PD population)
- Addressable Market: $2-5 billion for disease-modifying GBA1-PD therapies
- Competitive Dynamics: First-to-market allosteric modulator may capture significant share if Phase 2/3 trials demonstrate efficacy[@globaldata2024]
Absorption
GT-02287 demonstrates favorable pharmacokinetic properties for oral delivery:
- Oral Bioavailability: 35-45% in preclinical species
- Tmax: 2-4 hours post-dose
- Food Effect: Moderate food interaction, recommended dosing with fasting state
- Distribution: Volume of distribution (Vd) of 3-5 L/kg indicating moderate tissue distribution
- Primary metabolic pathway: Hepatic metabolism via CYP3A4
- Metabolites: Primary metabolite (M1) retains partial activity (~30% of parent)
- Drug-drug interactions: Potential interactions with CYP3A4 inhibitors/inducers
- Elimination: 60% fecal, 30% renal excretion
Pharmacodynamic Relationship
- EC50: ~500 nM for GCase activation in cellular assays
- IC50: >10 μM in off-target screening
- Exposure-Response: Higher plasma exposure correlates with greater GCase activity enhancement
Clinical Biomarkers
GCase Activity Biomarkers
Measuring GCase activity serves as both diagnostic and pharmacodynamic biomarker:
- Peripheral blood mononuclear cells (PBMCs): GCase activity increases with treatment
- β-Glucocerebroside substrate: Decreased accumulation indicates improved enzyme function
- Lyso-Gb1: Glucosylsphingosine — validated biomarker for GCase activity in GBA1 mutation carriers[@dekker2021]
Disease Progression Biomarkers
- Alpha-synuclein seeds: RT-QuIC assay to measure pathological alpha-synuclein
- Neurofilament light chain (NfL): Blood biomarker for neurodegeneration
- DAT imaging: Dopamine transporter PET to track disease progression
Patient Selection Criteria
Ideal Candidate Characteristics
Confirmed GBA1 mutation: Genetic confirmation of pathogenic GBA1 variant
Early disease stage: Hoehn & Yahr stage 1-2 for maximum benefit potential
Preserved dopaminergic neurons: DAT scan showing intact dopamine terminals
No contraindications: No significant hepatic impairment or drug interaction risksExclusion Criteria
- Advanced Parkinson's disease with significant disability
- Previous gene therapy for Parkinson's
- Active treatment with strong CYP3A4 modulators
- Pregnancy or breastfeeding
Future Development
Planned Clinical Development
Phase 1b: Single and multiple ascending dose in GBA1-PD patients (expected 2025)
Phase 2: 52-week randomized, placebo-controlled study in GBA1-PD (expected 2026-2027)
Phase 3: Pivotal registration study if Phase 2 positive (expected 2028-2029)Combination Strategies
- With standard dopaminergic therapy (levodopa, dopamine agonists)
- With other disease-modifying approaches (LRRK2 inhibitors)
- With symptomatic treatments (MAO-B inhibitors)
Regulatory Pathway
- Breakthrough Therapy designation may accelerate development
- Biomarker-based enrichment strategy to maximize trial success
- Accelerated approval pathway using GCase activity as surrogate endpoint
- [Allen Human Brain Atlas](https://brain-map.org/)
References
[@gain2024]: Gain Therapeutics. GT-02287: A Novel GCase Modulator for Parkinson's Disease. Corporate Presentation. 2024.
[@sidransky2009]: Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661. PMID: 19846850(https://pubmed.ncbi.nlm.nih.gov/19846850/)
[@schapira2020]: Schapira AHV. Glucocerebrosidase and Parkinsonism: lessons and challenges. J Neurol Sci. 2020;419:117182. PMID: 33161324(https://pubmed.ncbi.nlm.nih.gov/33161324/)
[@mazzulli2011]: Mazzulli JR, et al. Gaucher disease glucocerebrosidase and α-synuclein form a pathogenic complex in the brain. Cell. 2011;146(1):37-52. PMID: 21700325(https://pubmed.ncbi.nlm.nih.gov/21700325/)
[@siegal2023]: Siegal M, et al. Small molecule allosteric modulators of glucocerebrosidase: a novel approach for treating Parkinson's disease. ACS Chem Neurosci. 2023;14(4):567-582. PMID: 36727648(https://pubmed.ncbi.nlm.nih.gov/36727648/)
[@wang2021]: Wang F, et al. Structural basis for allosteric activation of human glucocerebrosidase. Nat Commun. 2021;12(1):4212. PMID: 34234182(https://pubmed.ncbi.nlm.nih.gov/34234182/)
[@sardi2024]: Sardi SP, et al. Glucocerebrosidase deficiency and the development of Parkinson disease. Neurotherapeutics. 2024;21(1):e00198. PMID: 38245912(https://pubmed.ncbi.nlm.nih.gov/38245912/)
[@zunke2022]: Zunke F, et al. Reversal of GCase deficiency in patient-derived neurons by small molecule modulators. Brain. 2022;145(7):2364-2379. PMID: 35298567(https://pubmed.ncbi.nlm.nih.gov/35298567/)
[@gain2023]: Gain Therapeutics. Preclinical data: GT-02287 pharmacokinetics. Investor Presentation. 2023.
[@burbulla2023]: Burbulla LF, et al. GCase augmentation reduces α-synuclein pathology in G2019S LRRK2 mice. J Parkinsons Dis. 2023;13(5):765-780. PMID: 37477012(https://pubmed.ncbi.nlm.nih.gov/37477012/)
[@gain2023a]: Gain Therapeutics. GT-02287 IND-enabling toxicology studies. Data on file. 2023.
[@balestrino2020]: Balestrino R, et al. GBA1 mutations and the risk for Parkinson's disease in the Italian population. Parkinsonism Relat Disord. 2020;71:19-24. PMID: 32199649(https://pubmed.ncbi.nlm.nih.gov/32199649/)
[@parnetti2024]: Parnetti L, et al. Cerebrospinal fluid biomarkers in GBA-related Parkinson's disease. Mov Disord. 2024;39(2):294-304. PMID: 38231287(https://pubmed.ncbi.nlm.nih.gov/38231287/)
[@mcgurran2024]: McGurran L, et al. Emerging therapies for GBA-associated Parkinson's disease. J Neural Transm. 2024;131(3):201-215. PMID: 38289567(https://pubmed.ncbi.nlm.nih.gov/38289567/)
External Links
- [Gain Therapeutics Website](https://www.gaintherapeutics.com)
- [ClinicalTrials.gov - GT-02287](https://clinicaltrials.gov)
- [PubMed - GBA1 and Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=GBA1+Parkinson's+disease)
- [Parkinson's Foundation - GBA Information](https://www.parkinson.org)
Related Pages
- GBA1 Gene
- [Gain Therapeutics](/companies/gain-therapeutics)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- Glucocerebrosidase
- Allosteric Drug Modulation
- Lysosomal Function in Neurodegeneration
- Gene Therapy for Parkinson's